Elisabetta Perrone

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Shaping the role of FDG PET in bladder cancer: current evidence and ongoing clinical trial.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Published: July 15, 2026

Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT.

Recurrent Metastatic Esthesioneuroblastoma: First-in-human α/β PRRT With Actinium-225/Lutetium-177-DOTA-LM3 SSTR Antagonist Achieving Partial Response After Failure of Lutetium-177-DOTATOC PRRT.

Journal: Clinical nuclear medicine
Published: April 18, 2026

Novel radiopharmaceuticals for bladder cancer evaluation.

Novel radiopharmaceuticals for bladder cancer evaluation.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Published: March 19, 2026

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy Using 177Lu-, 90Y-, and 225Ac-Labeled 3BP-3940: First Experience in 21 Different Advanced Malignancies.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 13, 2025

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Journal: Clinical nuclear medicine
Published: July 08, 2025

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Peptide Receptor Radionuclide Therapy (PRRT) Using Actinium-225- and Ac-225/Lutetium-177-Labeled (TANDEM) Somatostatin Receptor Antagonist DOTA-LM3 in Patients with Neuroendocrine Neoplasm: A Retrospective Study Concerning Safety and Survival.

Journal: Cancers
Published: June 30, 2025

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

First Autopsy-confirmed Complete Remission of Metastatic Neuroendocrine Neoplasm of Tailgut Cyst After a Single Cycle of Alpha-Peptide Receptor Radionuclide Therapy With [ 225 Ac]Ac-DOTA-LM3.

Journal: Clinical nuclear medicine
Published: June 23, 2025

In Vivo Versus In Vitro Somatostatin Receptor Expression in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Correlation Studies.

In Vivo Versus In Vitro Somatostatin Receptor Expression in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis of Correlation Studies.

Journal: International journal of molecular sciences
Published: June 05, 2025

Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.

Is Extraordinary Response and Long-Term Remission of Metastatic Castration-Resistant Prostate Cancer (mCRPC) After [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy Due to an Immunomodulatory Effect (Radiovaccination)? A Dual Center Experience on Super-Responders.

Journal: Cancers
Published: December 08, 2024

Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.

Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer.

Journal: Cancers
Published: December 05, 2024

TANDEM Peptide Receptor Radionuclide Therapy Using [ 225 Ac]Ac-/[ 177 Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.

TANDEM Peptide Receptor Radionuclide Therapy Using [ 225 Ac]Ac-/[ 177 Lu]Lu-DOTA-LM3 in a Patient With Parotid Gland Metastasis From Pancreatic Neuroendocrine Neoplasm.

Journal: Clinical nuclear medicine
Published: November 14, 2024

Axillary Skin Fibroblast Activation Protein Uptake After Chemo-immunotherapy on PET/CT and SPET/CT: A Mere Coincidence or Causality?

Axillary Skin Fibroblast Activation Protein Uptake After Chemo-immunotherapy on PET/CT and SPET/CT: A Mere Coincidence or Causality?

Journal: Clinical nuclear medicine
Published: October 05, 2024
Showing 1-12 of 20

Last Updated: 09/26/2026